Accuray (ARAY) 2025 Conference June 04, 2025 05:30 PM ET Speaker0 All right. Thank you, everyone, for attending. My name is Young Lee, one of the med tech analysts here at Jefferies. Really happy, to be with, Accuray. To my left, Accuray's CFO, Ali Pervais. Thanks for coming. I guess to begin, why don't we start a little bit high level. Just wanted to get an overview about end market growth, your competitive share position, and where Accuray sits or fits in the radiation oncology treatment paradigm. Speaker ...

More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in ...

Company Overview - Accuray Incorporated has introduced the CyberKnife® System at the CyberKnife Center Salzburg, marking the first use of this technology in Austria, which enhances access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT) [1][4] - The CyberKnife S7™ System allows for ultra-hypofractionated radiation therapy, delivering high doses of targeted radiation in just one to five outpatient sessions, significantly reducing the treatment time compared to conventional methods that often require 30-40 sessions [2][3] Clinical Impact - Evidence suggests that ultra-hypofractionation provides clinical outcomes comparable to conventional fractionation while reducing the number of treatments and overall care costs, leading to increased adoption of such treatments as standard care [3] - The CyberKnife System is viewed as a significant advancement in cancer care, enabling patients to receive precise and effective treatment in a shorter timeframe, which positively impacts their quality of life [5] Market Context - Cancer cases in Austria are projected to increase by nearly 25% from 2022 to 2040, highlighting the growing need for advanced cancer treatment options [4] - Despite Austria's strong reimbursement for oncology medications, the availability of radiotherapy equipment is 27% lower than the EU average, indicating a need for continued investment in technologies like the CyberKnife System to address this gap [4]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 暂定议程 报名：首届全球心血管大会 | 奖项报名倒计时 报名：首届全球骨科大会 | 奖项报名倒计时 2025年3月15日上午，2025中国医学装备大会在重庆悦来国际会议中心成功召开。相关政府部门领导、知名院士、医疗机构专家，研发生产企业、高校、科 研院所、投融资机构负责人等嘉宾出席大会。 中国医学装备协会理事长 侯岩介绍， 2024年中国医学装备市场规模达到 1.35万亿 元，同比增长 6％ 左右 。据了解，目前我国已形成22个大类1100多个 品类的产品体系，是世界上产品类别和品种最齐全的国家之一，产品广泛服务于临床应用，覆盖卫生健康各个领域。 目前大会已圆满落幕。本届展会中，哪些企业凭借创新亮相引起了行业关注？又有哪些前沿产品和技术成为焦点？思宇将全面回顾展会精彩亮点，供各位读 者参考。 # 美敦力 美敦力在本届大会上展出 近80款 全球创新产品， 包括 全球首发的PulseSelect一次性心脏脉冲场消融导管 ，以及多款前沿技术产品， 其中不乏首次展出及近 期获批的产品和技术。 其中包括中国首款获批的 PulseSelect一次性心脏 ...